showed that an 8-week semaglutide treatment in a gubra amylin (GAN) DIO NASH mouse model reduced food intake, body weight, and LFTs and improved lipid profile. This evidence concerns the gene IAPP and metabolic dysfunction-associated steatohepatitis.